Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Edesa Biotech | EB05 | hospitalized adults with COVID-19 who have or are at risk of developing acute respiratory distress syndrome | IND approved by the FDA |
| Reven Pharmaceuticals | Rejuveinix | hospitalized COVID-19 patients at high risk of progressing and developing acute respiratory distress syndrome or who are in hypoxemic respiratory failure | IND approved by the FDA |
| ImmunityBio NantKwest |
hAd5-COVID-19 | COVID-19 vaccine | first patient dosed in phase 1 trial |
| Abpro | ABP 300 | monoclonal antibody therapy against COVID-19 | patient dosing complete in phase 1 trial |
| Beyond Air | LungFit system (inhaled, high-dose nitric oxide) | adults hospitalized with acute viral pneumonia, including SARS-CoV-2 | approval to commence phase 2 trial in Israel |
| Arch Biosciences | LSALT peptide (Metablok) | prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19 | first patient dosed in phase 2 trial |
| Enlivex Therapeutics | Allocetra | severe and critical COVID-19 patients | first patients dosed in phase 2 trial |
| Dr. Reddy’s Labs | Sputnik V COVID-19 vaccine | COVID-19 | approval received from the Drug Controller General of India to conduct an adaptive phase 2/3 trial |
| Centogene | CentoSure | SARS-CoV-2 RT-PCR test | Emergency Use Authorization (EUA) granted by the FDA |
| Eurofins U.S. Clinical Diagnostics | at-home COVID-19 nasal PCR test | COVID-19 testing | EUA granted by the FDA |
| Orasure Technologies | DNA Genotek’s OMNIgene ORAL (OM-505, OME-505) saliva collection and stabilization device | COVID-19 testing | EUA granted by the FDA |
| Spectrum Solutions | SDNA-1000 saliva collection device | detecting COVID-19 infections | EUA granted by the FDA |
| Other Trials and Actions | |||
| Mereo Biotech | etigilimab | a defined series of tumor types, including biomarker-enriched and rare tumor cohort | IND approved by FDA |
| Adial Pharmacueticals | AD04 | alcohol use disorder | IND reactivated by FDA |
| Adicet Bio | ADI-001 | nonHodgkin’s lymphoma | IND approved by FDA |
| Intellia Therapeutics | NTLA-2001 | hereditary transthyretin amyloidosis with polyneuropathy | CTA approved by the UK Medicines and Healthcare products Regulatory Agency |
| Daiichi Sankyo | DS-1055 | patients with advanced or metastatic solid tumors who have progressed on standard treatment including checkpoint inhibitors | first patient dosed in phase 1 trial |
| Galera Therapeutics | GC4711 in combination with stereotactic body radiation therapy | non-small-cell lung cancer | first patient dosed in phase 1/2 trial |
| Onexo | AsiDNA | patients with acquired resistance to niraparib for second-line maintenance treatment of relapsed ovarian cancer | first patient treated in phase 1b/2 trial |
| Aslan Pharmaceuticals | ASLAN004 | moderate to severe atopic dermatitis | initiation of third dose cohort of phase 2 trial |
| Oxeia Biopharmaceuticals | OXE103 | patients within 28 days of injury who are highly symptomatic of concussion | initiation of phase 2 trial |
| Trevi Therapeutics | Haduvio (nalbuphine ER) | chronic cough in patients with idiopathic pulmonary fibrosis | patient screening resumed in phase 2 trial |
| Imara | IMR-687 | beta-thalassemia | first patient dosed in phase 2b trial |
| Cyclo Therapeutics | Trappsol Cyclo (Hydroxypropyl-?-cyclodextrin) | Niemann-Pick Disease Type C1 | initiation of phase 3 trial |
| Evofem Biosciences | EVO100 | prevention of urogenital chlamydia and gonorrhea in women | first patient enrolled in phase 3 trial |
| Mycovia Pharmaceuticals | oteseconazole (VT-1161) | recurrent vulvovaginal candidiasis | last patient visit complete in phase 3 trial |
| Versantis AG | VS-01 | urea cycle disorders | Rare Pediatric Disease designation granted by the FDA |
| Genentech | Venclexta (venetoclax) in combination with azacitidine, or decitabine or low-dose cytarabine | newly diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy | approved by the FDA |
| Embody | Tapestry Biointegrative Implant | tendon and ligament repair | approved by the FDA |
Upcoming Events
-
25May
-
28Jun
-
16Oct
